biotech · Parkinson Disease · Amyotrophic Lateral Sclerosis · DNLI
Denali Therapeutics
Denali Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker DNLI. Primary therapeutic focus areas include Parkinson Disease, Amyotrophic Lateral Sclerosis, Fron
161 Oyster Point Blvd, South San Francisco, California 94080, US HQ
2015 Founded
567 Employees
Public company Type
DNLI · NYSE Ticker
Company details
- Status
- Public
- HQ
- 161 Oyster Point Blvd, South San Francisco, California 94080, US
- Founded
- 2015
- Employees
- 567
- Programs
- 23
- Drugs
- 10
- Patents
- 42
DNLI-E-0002
Phase 2 · other · Hunter Syndrome (Mucopolysaccharidosis Type II [MPS II])
DNLI-E-0002 for Hunter Syndrome (Mucopolysaccharidosis Type II [MPS II]) is a Phase 2 program (other) at Denali Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code DNLI-E-0002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Denali Therapeutics
- Phase
- Phase 2
- Modality
- other
- Indication
- Hunter Syndrome (Mucopolysaccharidosis Type II [MPS II])
- Status
- active
- Trials
- 1